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OBJECTIVES The purpose of this study was to determine whether verapamil has rate-dependent effects on
the atrial effective refractory period (AERP).
BACKGROUND Block of calcium current (ICa) and rapid component of the delayed rectifier potassium current
(IKr) by verapamil is frequency-dependent. This may result in variable effects of verapamil on
the AERP, depending on the rate.
METHODS The subjects of this study were 30 adults with a mean age of 45  13 years who did not have
structural heart disease. In 20 subjects, the AERP was measured at basic drive cycle lengths
(BDCLs) of 650 to 250 ms, in 50 ms decrements, before and after infusion of 0.1 mg/kg
verapamil. The effective refractory periods (ERPs) were measured in the setting of autonomic
blockade in 10 subjects and without autonomic blockade in 10 subjects. Ten subjects served
as a control group and received a saline infusion instead of verapamil.
RESULTS Verapamil significantly prolonged the AERP at BDCLs of 650 to 500 ms (p  0.01 or p 
0.05) and significantly shortened the ERP at BDCLs of 300 and 250 ms (p  0.01). In the
control group, there were no significant differences between the baseline and post-saline
measurements of ERP.
CONCLUSIONS Verapamil prolongs AERP at slow rates and shortens AERP at rapid rates. These findings are
consistent with a predominant effect on ICa at rapid rates and a predominant effect on IKr at
slow rates. (J Am Coll Cardiol 2003;41:446–51) © 2003 by the American College of
Cardiology Foundation
Verapamil blocks both the slow inward calcium current and
the delayed rectifying current (1). Block of calcium current
(ICa) and rapid component of the delayed rectifier potassium
current (IKr) by verapamil is frequency-dependent (1),
suggesting that verapamil may have variable effects on atrial
refractoriness depending on the rate. However, no prior
studies have directly assessed the rate-dependent effects of
verapamil on the atrial effective refractory period (AERP).
Therefore, this study was designed to determine the effect of
verapamil on the AERP over a range of pacing rates.
METHODS
Characteristics of subjects. The subjects of this study
consisted of 30 patients referred to the University of
Michigan Medical Center for radiofrequency catheter abla-
tion of supraventricular tachycardia. The inclusion criteria
consisted of sinus rhythm as the baseline rhythm and a
structurally normal heart. The exclusion criteria were as
follows: treatment with any medication within 72 h of the
procedure; a contraindication to propranolol, atropine, or
verapamil; or failure to achieve a stable catheter position
within the right atrial appendage, with a pacing threshold
consistently 1.0 mA. No patient had been treated with
amiodarone. Among 39 patients recruited for the study, 9
patients were withdrawn because they developed atrial
fibrillation (AF) in the course of the study protocol. There-
fore, the study protocol was successfully completed in 30
subjects.
There were 7 men and 23 women, and their mean age
was 45  13 years. In accord with the selection criteria for
the study, all patients had a normal echocardiogram. The
mean left ventricular ejection fraction was 0.60  0.03. The
mechanism of tachycardia was atrioventricular (AV) nodal
re-entrant tachycardia in 22 patients, orthodromic AV
re-entrant tachycardia in 4 patients, paroxysmal atrial flutter
in 2 patients, and idiopathic right ventricular tachycardia in
2 patients. The effects of verapamil were tested in 20
patients, and 10 patients served as a control group. There
were no significant differences in the demographic or
clinical characteristics of the subjects in the two groups.
Electrophysiology procedure. The electrophysiologic pro-
cedures were performed in the fasting state. After informed
consent was obtained, three quadripolar electrode catheters
with an interelectrode spacing of 2-5-2 mm were positioned
in the high right atrium, His-bundle position, and right
ventricular apex. Patients were sedated with midazolam and
fentanyl and received 3,000 U of heparin. Several electro-
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cardiographic leads and the intracardiac electrograms were
displayed on a screen and recorded digitally (EP Med
Systems, Inc., Mount Arlington, New Jersey). Pacing was
performed with a programmable stimulator (EP Med Sys-
tems, Inc.) with stimuli that had a pulse width of 2 ms and
an amplitude three times the pacing threshold.
Study protocol. The study protocol was approved by the
Human Research Committee and written consent was
obtained before the electrophysiology procedure. The study
protocol was performed after completion of the radiofre-
quency catheter ablation procedure. A quadripolar electrode
catheter was positioned in the right atrial appendage such
that there was a stable pacing threshold 1 mA. The mean
pacing threshold was 0.8  0.1 mA. This catheter was used
to measure the AERP. A second electrode catheter was
positioned against the low lateral right atrial wall to record
an atrial electrogram. Pharmacologic autonomic blockade
was achieved in 10 subjects in the verapamil group and in
the 10 subjects in the control group by infusion of 0.04
mg/kg of atropine and 0.2 mg/kg of propranolol over 5 min
(2). The mean body weight of the 20 subjects was 64  15
kg, with no significant difference between the verapamil and
control groups.
Whenever possible, the AERP was measured at basic
drive cycle lengths (BDCLs) of 650 to 250 ms, at decre-
ments of 50 ms. At each BDCL, there was a conditioning
train of 100 S1s. During continuous pacing, an atrial
extrastimulus then was introduced after every eighth S1,
with an initial coupling of 150 ms and with no pauses in the
drive train. The coupling interval of the extrastimulus was
increased in steps of 5 ms until there was atrial capture. The
AERP was defined as the longest S1S2 coupling interval
that failed to result in atrial capture.
In 10 patients in the verapamil group, the effective
refractory periods (ERPs) first were measured after auto-
nomic blockade, then again after infusion of verapamil. In
the other 10 patients in the verapamil group, autonomic
blockade was not used. The dose of verapamil was 0.1
mg/kg over 3 min, followed 5 min later by an infusion of
0.005 mg/kg/min until the study protocol was completed
(3,4). The mean total verapamil dosage was 7.7  2.3 mg.
The sinus cycle length sometimes was 650 ms after
autonomic blockade; therefore, among the patients who
received autonomic blockade, the AERP could be measured
in only four patients at a BDCL of 650 ms and in five
patients at a BDCL of 600 ms. The AERP was measured in
all 10 patients at BDCLs of 550 to 250 ms.
In the control group, the AERP was measured in exactly
the same fashion as in the verapamil group. The ERPs were
measured after autonomic blockade, then after infusion of
0.1 ml/kg of saline, followed 5 min later by infusion of saline
at a rate of 0.005 ml/kg/min until the study protocol was
completed. Because the sinus cycle length after autonomic
blockade was 650 ms in some patients, the AERP could
be measured in only two patients at a BDCL of 650 ms and
in six patients at a BDCL of 600 ms. The AERP was
measured in all 10 patients at BDCLs of 550 to 250 ms.
The blood pressure was measured periodically during the
study protocol with an automated brachial artery cuff.
Statistical analysis. Continuous variables are expressed as
mean 1 SD. Student’s t test and the Fisher exact test were
used to compare clinical and demographic variables between
the verapamil group and the control group. Analysis of
variance with repeated measures was used to compare the
ERPs before and after verapamil or saline at different
BDCLs. The Newman-Keuls test was used for post-hoc
analysis, and the p values presented in Tables 1 to 3 refer to
the results of the Newman-Keuls multiple comparisons test.
In the autonomic blockade/verapamil group, ERPs at BD-
CLs of 650 and 600 ms were feasible in only four and five
patients, respectively, and a paired t test was used for
comparing the ERP before and after verapamil at these
Abbreviations and Acronyms
AERP  atrial effective refractory period
AF  atrial fibrillation
AV  atrioventricular
BDCL  basic drive cycle length
ERP  effective refractory period
ICa  calcium current
IKr  rapid component of the delayed rectifier
potassium current
Table 1. AERPs Before and After Infusion of Verapamil
During Autonomic Blockade
BDCL
(ms)
No. of
Patients
Baseline
AERP (ms)
Post-Verapamil
AERP (ms) p Value
650 4 230  9 250  12  0.01
600 5 228  8 244  13  0.01
550 10 218  14 229  14  0.01
500 10 216  14 224  11  0.05
450 10 214  13 217  13 0.6
400 10 210  9 207  13 0.4
350 10 207  10 202  12 0.2
300 10 196  7 187  8  0.01
250 10 186  6 173  9  0.01
Effective refractory periods expressed as mean  SD.
AERP  atrial effective refractory period, BDCL  basic drive cycle length.
Table 2. AERPs Before and After Infusion of Verapamil, in the
Absence of Autonomic Blockade
BDCL
(ms)
No. of
Patients
Baseline
AERP (ms)
Post-Verapamil
AERP (ms) p Value
650 10 221  14 232  16  0.01
600 10 218  16 229  15  0.01
550 10 215  17 222  17 0.1
500 10 211  18 215  15 0.6
450 10 208  17 212  16 0.6
400 10 204  13 202  16 0.7
350 10 198  13 196  16 0.7
300 10 190  11 183  13  0.05
250 10 180  12 164  12  0.01
Effective refractory periods expressed as mean  SD.
Abbreviations as in Table 1.
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drive cycle lengths. Because the sample size in the control
group at a drive cycle length of 650 ms was only two, this
data point was excluded from the analysis. A p value of
0.05 was considered statistically significant.
RESULTS
Sinus cycle length and blood pressure. In the verapamil
group, among the patients who received autonomic block-
ade, the pre-verapamil sinus cycle length of 650  94 ms
lengthened to 688  94 ms after infusion of verapamil (p 
0.05). In the patients in the verapamil group who did not
receive autonomic blockade, the pre-verapamil sinus cycle
length of 771  35 ms shortened to 745  54 ms after
infusion of verapamil (p  0.05). In the control group, the
baseline sinus cycle length (after autonomic blockade) was
651  63 ms, and 649  67 ms after infusion of saline (p
 1.0).
In the verapamil group, among the patients who received
autonomic blockade, the pre-verapamil mean blood pressure
was 75  7 mm Hg, compared with 70  7 mm Hg after
infusion of verapamil (p  0.3). In the patients in the
verapamil group who did not receive autonomic blockade,
the pre-verapamil mean blood pressure was 88  11 mm
Hg, compared with 84  11 mm Hg after infusion of
verapamil (p 0.3). In the control group, the baseline mean
blood pressure (after autonomic blockade) was 78  8 mm
Hg, and 81  3 mm Hg after infusion of saline (p  0.8).
AERPs in the verapamil group. The AERPs measured at
BDCLs of 650 to 250 ms before and after infusion of
verapamil in the setting of autonomic blockade are shown in
Table 1 and Figure 1. Compared with baseline, verapamil
resulted in a significant lengthening of the AERP at
BDCLs of 650, 600, 550, and 500 ms, and in a significant
shortening of the AERP at BDCLs of 300 and 250 ms.
The AERPs measured at BDCLs of 650 to 250 ms
before and after infusion of verapamil in the absence of
autonomic blockade are shown in Table 2 and Figure 2.
Compared with baseline, verapamil resulted in a significant
lengthening of the AERP at BDCLs of 650 and 600 ms,
and in a significant shortening of the AERP at BDCLs of
300 and 250 ms.
AERPs in the control group. Both before and after
infusion of saline, the AERP progressively shortened as the
BDCL decreased from 600 to 250 ms. In the control group,
there were no significant changes in the AERPs measured at
BDCLs of 600 to 250 ms before and after infusion of saline
(Table 2, Fig. 3)
DISCUSSION
Rate-dependent effects of verapamil. The results of this
study demonstrate that verapamil has opposite effects on the
Table 3. AERPs in Control Subjects Before and After Saline
Infusion, During Autonomic Blockade
BDCL
(ms)
No. of
Patients
Baseline
AERP (ms)
Post-Saline
AERP (ms) p Value
600 6 227  24 224  24 1.0
550 10 224  19 222  16 1.0
500 10 224  19 223  19 1.0
450 10 222  19 221  21 1.0
400 10 217  19 216  17 1.0
350 10 212  13 211  10 1.0
300 10 198  11 199  11 1.0
250 10 186  10 187  7 1.0
Effective refractory periods expressed as mean  SD.
Abbreviations as in Table 1.
Figure 1. Atrial effective refractory periods (AERP) before and after infusion of verapamil, measured at basic drive cycle lengths (BDCL) of 650 to 250
ms, in the presence of autonomic blockade. Error bars  1 standard deviation. *p  0.01, †p  0.05.
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AERP that are rate-dependent. At relatively slow heart
rates, verapamil prolongs the atrial ERP, whereas at rela-
tively rapid heart rates, the AERP is shortened by vera-
pamil. These rate-dependent effects of verapamil on atrial
refractoriness are consistent with a variable predominance of
ICa and IKr blockade by verapamil at slow and rapid rates,
respectively.
Underlying mechanisms. The mechanisms underlying the
variable effect of verapamil on AERP may be explained by
rate-dependent block of calcium and potassium channels by
verapamil. Block of ICa by verapamil decreases the plateau
calcium current, thereby shortening the action potential
duration and the ERP (5), and blockade of ICa by verapamil
is enhanced at rapid rates (1). However, verapamil also
blocks IKr (6), resulting in lengthening of the action poten-
tial duration and ERP that may be manifest at relatively
slow rates. Therefore, use-dependent block of ICa and
reverse use-dependent prolongation of action potential du-
ration may underlie the variable effects of verapamil on the
AERP observed in this study.
Figure 2. Atrial effective refractory periods (AERP) before and after infusion of verapamil, measured at basic drive cycle lengths (BDCL) of 650 to 250
ms, in the absence of autonomic blockade. Error bars  1 standard deviation. *p  0.01, †p  0.05.
Figure 3. Atrial effective refractory periods (AERP) in the control group, before and after infusion of saline, at basic drive cycle lengths (BDCL) of 600
to 250 ms. Error bars 1 standard deviation. There were no significant differences between the effective refractory periods measured before and after saline
infusion.
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Effect of verapamil on atrial refractoriness. In some prior
studies, verapamil was found to shorten the AERP, whereas
in others, it was found to lengthen the ERP. The rate-
dependent effects of verapamil demonstrated in the present
study may explain the variable effects of verapamil on atrial
refractoriness in prior studies. For example, in a prior
experimental study, verapamil was found to shorten the
AERP (7). In that study, the BDCL at which the ERP was
measured was 300 ms. In contrast, in a prior clinical study,
verapamil was found to lengthen the AERP, and in that
study, the BDCL was 500 ms (8). Based on the results of
the present study, the opposite effects of verapamil on atrial
refractoriness reported in prior studies are attributable, at
least in part, to different BDCLs used to measure the
refractory period.
Effects of verapamil in the setting of AF. Verapamil has
been demonstrated to shorten the AF cycle length (7,9–11).
The AF cycle length is directly related to the AERP
(12,13). Therefore, because the atrial cycle length during
AF typically is250 ms, the effect of verapamil on AF cycle
length is consistent with the results of the present study, in
which verapamil shortened the AERP at BDCLs300 ms.
Shortening of the AERP when the atrial rate is rapid is
likely to explain why verapamil may prolong an episode of
AF and lower the probability of spontaneous cardioversion
(7,9,11,14,15).
Although verapamil decreases the AF cycle length, once
sinus rhythm is restored, it attenuates the post-AF short-
ening of AERP caused by AF (8,11,16,17). This observa-
tion also is consistent with the results of the present study.
Because the atrial rate during sinus rhythm typically is600
ms, verapamil would no longer be expected to shorten atrial
refractoriness post-AF. During sinus rhythm, verapamil’s
predominant effect is to lengthen the AERP. This may be
one of the reasons that verapamil decreases the susceptibility
towards immediate recurrences of pacing-induced or spon-
taneous AF (8,18,19).
Autonomic blockade. To prevent the confounding effects
of fluctuations in autonomic tone that would be expected to
occur in response to variable sedation, rapid pacing, and
verapamil infusion, the effects of verapamil on atrial refrac-
toriness were determined in the setting of pharmacologic
autonomic blockade. However, in the clinical setting, pa-
tients who are treated with verapamil typically are not
autonomically blocked. Therefore, to mimic the clinical
setting, the effects of verapamil also were tested in the
absence of autonomic blockade. In the absence of auto-
nomic blockade, the effects of verapamil were attenuated at
BDCLs of 550 and 500 ms. This may be attributable to
sympathetic activation that occurred in response to vera-
pamil infusion, as reflected by the shortening of sinus cycle
length. However, the effects of verapamil on atrial refracto-
riness at the longest and shortest BDCLs were manifest
even in the absence of autonomic blockade, demonstrating
that the results of this study are applicable to the clinical
setting.
Pharmacologic autonomic blockade was achieved by in-
fusion of a single dose of propranolol and atropine at the
outset of the protocol, and additional dosages of these
agents were not administered in the course of the study
protocol, which had a duration of approximately 30 min.
The degree of autonomic blockade, therefore, may have
progressively lessened over time. However, in the control
group, the AERPs measured before and after the infusion of
saline did not differ significantly at any BDCL. Because the
duration of the study protocol was the same in the verapamil
and control groups, these data demonstrate that temporal
changes in the degree of autonomic blockade during the
study protocol were not a confounding variable.
Prior studies. Rate-dependent effects of verapamil have
been demonstrated previously in experimental and clinical
studies, but only with respect to AV nodal conduction
(20,21). Block of the calcium current in the AV node is
manifest as slowing of conduction. Accordingly, the degree
of prolongation in AV nodal conduction caused by vera-
pamil was found to progressively increase as the BDCL
shortened from 1,500 to 300 ms in dogs (21), and from
approximately 800 to 350 ms in humans (20).
In these prior studies, the AERP was not measured
(20,21). The present study demonstrates that rate-
dependent depression of the calcium current also is demon-
strable in the atrium, where block of ICa is manifest as a
shortening of the ERP.
Study limitations. A limitation of this study is that the
AERP was measured only in the right atrial appendage.
Therefore, it is not known whether the effects of verapamil
demonstrated in this study are site-dependent.
A second limitation is that all of the subjects in this study
had structurally normal hearts, and it is possible that the
results of the study do not apply to patients who have
structural heart disease.
None of the subjects in this study had AF. Whether the
effects of verapamil demonstrated in this study also are
applicable in the setting of electrical and structural remod-
eling associated with AF remains to be determined.
Lastly, the BDCLs used in this study were not tested in
random order, but always in the same sequence of longest to
shortest cycle length. This was done to avoid having to wait
several minutes for the effects of a rapid rate on atrial
refractoriness to dissipate before measuring the ERP at a
slower basic drive rate (22). The possibility that the ERP
measurements were affected by the sequence of BDCLs
cannot be ruled out.
Conclusions. Although the effects of several antiarrhyth-
mic drugs are either use-dependent or reverse use-
dependent, some drugs may display both use- and reverse
use-dependence (23). For example, block of sodium chan-
nels by quinidine is use-dependent, whereas the prolonga-
tion of action potential duration that occurs as a conse-
quence of quinidine-induced IKr block is reverse use-
dependent (23). Verapamil is similar in that its effects on
AERP display both use-dependence and reverse use-
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dependence. Shortening of atrial refractoriness at rapid rates
and lengthening of refractoriness at relatively slow rates may
explain how verapamil can exert either a proarrhythmic or
antiarrhythmic effect on AF, depending on the atrial rate.
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